MIR490 (MicroRNA 490)

Priorities for validation include reporter assays, gene/protein modulation, phenotypic rescue, and in vivo testing in MP-exposed models. Collectively, our results nominate miRNAs as candidate tools to interrogate and potentially mitigate MP-associated carcinogenic mechanisms.

Therapeutic combination index analysis indicated robust synergy between FMNT and 5-FU, with combination therapy achieving superior tumor growth inhibition compared to monotherapies. Collectively, our findings uncover a novel miR-490-3p/ABCC2 regulatory mechanism underlying FMNT's antitumor activity and highlight its potential for chemosensitization through ABCC2 inhibition, providing a strong rationale for flavonoid-based adjuvant therapy in CRC management.

[This retracts the article DOI: 10.3892/etm.2018.7042.].

Perindopril inhibits myocardial apoptosis in mice with acute myocardial infarction through TLR4/NF-κB pathway...SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway...Natural killer cell-derived exosome-entrapped paclitaxel can enhance its anti-tumor effect...Antidiabetic drug metformin mitigates ovarian cancer SKOV3 cell growth by triggering G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signaling pathway...These articles have been retracted. The Publisher apologizes for any inconvenience this may cause.

MiR-490-5p directly regulated HDAC2 expression, thereby modulating the growth and metastatic capacity of OS cells. The miR-490-5p/HDAC2 axis could serve as a promising therapeutic target for OS.

Serum exo-miRNAs could be promising candidates for precise diagnosis and treatment of PDAC. Exo-miR-519a/522-5p promotes PDAC cellular invasiveness by enhancing Warburg effect through intercellular transportation.

Based on the PPI network, a functional enrichment analysis of the target proteins was also carried out. (4) We identified an miRNA panel and several deregulated mRNAs that could play an important role in tumor development and distinguish GBM patients from healthy controls with high sensitivity and specificity using total RNA isolated from tissue samples.

Therefore, all parties agree that the article must be retracted. The authors did not respond to the notice regarding the retraction of their article.

Finally, immunohistochemical examination confirmed the expression of some candidate genes in clinical samples. These findings shed light on the molecular causes of OC and CC and will aid the identification of novel targets for future research regarding these cancers, including their diagnosis and treatment.

Logistic regression analysis showed that this miRNA signature was an independent risk factor for DM of lung adenocarcinoma. Next, target genes of the eight miRNAs were predicted, and enrichment analysis showed that these target genes were enriched in a variety of pathways, including pathways in cancer, herpes simplex virus I infection, PI3K-Akt pathway, MAPK pathway, Ras pathway, etc. This miRNA signature has good efficacy in predicting DM of lung adenocarcinoma and has the potential to be a predictor of DM of lung adenocarcinoma.

MiR-490-3p upregulation inhibited cell proliferation and metastasis but promoted the cell apoptosis and cell-cycle arrest in osteosarcoma via the regulation of CDCA8/ATF3 by targeting NUSAP1. Thus, miR-490-3p might be a potential therapeutic target for the treatment of osteosarcoma.

Based on RNA correlation analysis, 1, 23, and 2 potential ceRNA regulatory axes were identified in STAD (PVT1/miR-490-3p/HMGA2), LIHC (DLX6-AS1/miR-139-5p/TOP2A, etc.), and COAD (STRCP1 & LINC00488/miR-142-3p/GAB1), respectively. This study advances the understanding of ceRNA networks in digestive cancers, highlighting RNA biomarkers with potential as therapeutic targets for personalized treatment strategies.